NCT03281824: Clinical Study of ALT-P7 to Determine Safety, Tolerability and Pharmacokinetics in Breast Cancer Patients

NCT03281824
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Enrolling by invitation
Phase 1
Drug Category: Therapeutic Antibody

Key Eligibility Criteria:

Gender: Female
Age: 19 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Untreated or symptomatic brain metastasis, or brain metastasis requiring radiation, surgery or corticosteroid therapy
https://ClinicalTrials.gov/show/NCT03281824

Comments are closed.

Up ↑